Apotex Gets First US Tentative Approval for Generic Semaglutide Injection

Apotex has received the U.S. FDA’s first Tentative Approval for its Abbreviated New Drug Application for semaglutide injection. In short, Apotex says, it is a “significant milestone” opening a pathway to a generic version of Novo Nordisk’s Ozempic.

Apotex Partners With Orbicular

The treatment was developed through a strategic partnership with Orbicular Pharmaceutical Technologies, said Apotex Chief Corporate Development Officer Barry Fishman. This collaboration brought together sophisticated development capabilities such as advanced analytical characterization and deep process understanding, Apotex says.

“This is a clear demonstration of what true partnership can achieve,” Fishman said. “This milestone reflects Apotex’s leadership in bringing together complementary strengths, a shared purpose, and an unwavering commitment to execution excellence.”

M.S. Mohan, PhD, Orbicular Managing Director, also responded to the FDA decision.

“Technical equivalence for complex peptide products requires deep scientific rigor, advanced analytical precision, and … highly disciplined development,” Mohan said. “We are proud to have supported Apotex in this important program. Their regulatory leadership coupled with Orbicular’s development and execution excellence were central to securing FDA Tentative Approval.”

Importance of Generic Semaglutide Injection

With this approval, Apotex says it hopes to expand affordable access to complex peptide therapies for U.S. patients. The company’s focus has traditionally been on advancing complex generics that reduce costs for both patients and payers. In so doing, Apotex says it is working toward supporting a more sustainable healthcare system.

As for the next steps after the FDA Tentative Approval, Apotex’s semaglutide injection may become eligible for final approval. At that time, the company says, it will broaden patient access to an important therapeutic area where affordability is challenging.